Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Trastuzumab biosimilar by Tanvex BioPharma for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Trastuzumab biosimilar is under clinical development by Tanvex BioPharma and currently in Pre-Registration for Human Epidermal Growth Factor Receptor 2...